抗血素-氨酸共价复合物:一种可能的替代氨酸,用于预防动脉血栓形成
Anthony K C Chan1, Janusz Rak, Leslie Berry
1Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada.
Circulation
|July 10, 2002
概括
在子中,一种新型的共价抗素-氨酸复合物 (ATH) 与标准氨酸 (SH) 相比,显示出优异的动脉血栓形成控制. ATH在显著减少出血的情况下实现了更大的抗血栓作用,为血栓症治疗提供了有前途的替代方案.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
- 血栓形成模型的模型
背景情况:
- 肝类药物通过抗血素 (AT) 和肝素辅因子II的辅因子活性产生抗凝剂作用.
- 血栓形成患者的血栓素通常受到标准肝素 (SH) 介导的失活的保护.
- 开发了一种新的共价AT-氨酸复合物 (ATH),以克服SH的局限性.
研究的目的:
- 为了比较SH和ATH的抗血栓和出血特性.
- 在子动脉血栓形成模型中评估ATH的疗效.
主要方法:
- 血管壁损伤和子狭窄引起的动脉血栓形成.
- 使用远端流量探针监测血流.
- SH (62.5187.5 IU/kg) 和ATH (1665 IU/kg) 的剂量在90分钟内使用.
- 从皮肤切口中累积的血液损失评估了安全性.
主要成果:
- ATH表现出比SH更大的抗血栓作用,由凝块重量,血液流动和血管通透度证明.
- 通过ATH (3365 IU/kg) 与SH (125.0187.5 IU/kg) 实现了完全的血栓分辨率.
- 在相当的血管通透度 (5060%),ATH诱导的血流量比SH (154.6μL) 少2.6倍 (60.2μL).
结论:
- 在实验模型中,ATH有效控制了动脉血栓形成.
- 与其SH前体相比,ATH显示出更高的疗效.
- 在没有明显出血的情况下,ATH提供了有效的血栓形成控制.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Extrinsic and Intrinsic Pathways of Hemostasis
11.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.1K
Venous Thrombosis I: Introduction
834
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
834
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482


